<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000641130">
  <TermName>mapatumumab</TermName>
  <TermPronunciation>(ma-puh-TOO-moo-mab)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance being studied in the treatment of some types of cancer. It binds to a protein called TRAIL R1 on the surface of some tumor cells.  This may kill the tumor cells. Mapatumumab is a type of monoclonal antibody. Also called anti-TRAIL R1-mAb and HGS-ETR1.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000722514" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;mapatumumab&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000722513" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;mapatumumab&quot;" language="es" id="_4"/>
  <SpanishTermName>mapatumumab</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento de ciertos tipos de cáncer. Se une a una proteína llamada TRAIL R1 que se encuentra en la superficie de algunas células tumorales, y en ocasiones las destruye. El mapatumumab es un tipo de anticuerpo monoclonal. También se llama AcM anti-TRAIL R1 y HGS-ETR1.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2009-05-19</DateFirstPublished>
</GlossaryTerm>
